|

CLN-049 Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 1: 1

Top Sponsors

  • Cullinan Therapeutics Inc.1

Indications

  • Relapsed/Refractory Acute Myeloid Leukemia (AML)1
  • Myelodysplastic Syndrome(MDS)1
  • Cancer1

Birmingham, Alabama1 trial

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

University of Alabama O'Neal Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.